Gene and cell‐based therapies for inherited retinal disorders: An update
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Retinal degenerations present a unique challenge as disease progression is irreversible and the retina has little regenerative potential. No current treatments for inherited retinal disease have the ability to reverse blindness, and current dietary supplement recommendations only delay disease progression with varied results. However, the retina is anatomically accessible and capable of being monitored at high resolution in vivo. This, in addition to the immune‐privileged status of the eye, has put ocular disease at the forefront of advances in gene‐ and cell‐based therapies. This review provides an update on gene therapies and randomized control trials for inherited retinal disease, including Leber congenital amaurosis, choroideremia, retinitis pigmentosa, Usher syndrome, X‐linked retinoschisis, Leber hereditary optic neuropathy, and achromatopsia. New gene‐modifying and cell‐based strategies are also discussed. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · cited 1×
“This strategy was shown to be applicable to eukaryotes, including human cells, when fused to transcription modulators [Gilbert et al., 2013; Maeder et al., 2013; Gilbert et al., 2014].”
BackgroundDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728 · cited 2×
“CRISPRi is precise and affects gene expression at the DNA level with minimal off-target effects, which is an improvement upon the previous strategy involving RNAi, which decreases expression at the mRNA level [Gilbert et al., 2014].”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“…that has shown beneficial results in treating inherited retinal disease [Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009; Banin et al., 2010; Simonelli et al., 2010; Jacobson et al., 2012; Testa et al.,…”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“…phase I/II gene therapy trials assessed the effects of unilateral, subretinal administration of AAV-RPE65, which demonstrated short-term rescue [Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009; Banin et…”
BackgroundSchwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
CRISPR RNA–guided activation of endogenous human genes
Maeder, M. L., Linder, S. J., Cascio, V. M., Fu, Y., Ho, Q. H., & Joung, J. K. (2013) · Nature Methods · doi:10.1038/nmeth.2598 · Cited by 1,249
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“An AAV-mediated therapeutic gene delivery was used in a naturally occurring canine model for LCA2 (RPE65 / ) in 2001, which led to the long-term restoration of vision in treated dogs [Acland et al., 2001].”
Cited by
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
“This slow progression has been cited as advantageous because it provides a wide window for administering the treatment (Sengillo et al., 2016; Dimopoulos et al., 2018: Pennesi et al., 2019; Mitsios et al., 2018), yet it complicates outcome assessments in the absence of robust natural disease history studies.”
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Self-citationGene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
“Genetic therapy has been investigated in inherited retinal diseases such as Leber’s congential amaurosis (LCA), choroideremia, retinitis pigmentosa (RP), Usher’s disease, Stargardt’s disease, Leber’s hereditary optic neuropathy, achromatopsia, and X-linked retinoschisis [11].”
BackgroundCiulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Kovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases
Xu, C. L., Cho, G. Y., Sengillo, J. D., Park, K. S., Mahajan, V. B., & Tsang, S. H. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00046 · Cited by 19
Self-citationCRISPR/Cas9 genome surgery for retinal diseases
Xu, C. L., Park, K. S., & Tsang, S. H. (2018) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.05.001 · Cited by 14
Self-citation
Metadata
- Authors
- Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H.
- Venue
- American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Publisher
- Wiley
- Published
- 2016-11-08
- Volume
- 172
- Issue
- 4
- Pages
- 349-366
- ISSN
- 1552-4868 (ISSN-L)
- 1552-4876
- OpenAlex
- W2556045776
- Cited by
- 65
- References
- 41
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.